Advertisement
Canada markets close in 2 hours 4 minutes

  • S&P/TSX

    22,425.27
    +125.44 (+0.56%)
     

  • S&P 500

    5,297.45
    +0.35 (+0.01%)
     

  • DOW

    39,937.18
    +67.80 (+0.17%)
     

  • CAD/USD

    0.7346
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    79.83
    +0.60 (+0.76%)
     

  • Bitcoin CAD

    90,827.02
    +2,385.55 (+2.70%)
     

  • CMC Crypto 200

    1,366.29
    -7.55 (-0.55%)
     

  • GOLD FUTURES

    2,417.60
    +32.10 (+1.35%)
     

  • RUSSELL 2000

    2,095.60
    -0.64 (-0.03%)
     

  • 10-Yr Bond

    4.4240
    +0.0470 (+1.07%)
     

  • NASDAQ

    16,680.05
    -18.27 (-0.11%)
     

  • VOLATILITY

    12.17
    -0.25 (-2.01%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • CAD/EUR

    0.6755
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS TREAD WATER WITH DOW EYEING 40,000 MARK AGAIN

GameStop shares sink further after games retailer said it expects Q1 sales to decline

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

Phathom Pharmaceuticals
·1 min read
Phathom Pharmaceuticals
Phathom Pharmaceuticals

  • Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress.

A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

ADVERTISEMENT

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.